ZyVersa Therapeutics (ZVSA) AI Stock Analysis

• Market Cap: $2.41M
• Dividend Yield: N/A
• Average Volume (3M): 4.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: N/A
• EPS Growth: 99.39%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -11.58
• Shares Outstanding: 3,619,456
• 10 Day Avg. Volume: 13,041,161
• 30 Day Avg. Volume: 4,427,471
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.00
• Price Target Upside: 2930.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.

ZyVersa Therapeutics Business Overview & Revenue Model

Company Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

How the Company Makes Money

ZyVersa Therapeutics makes money primarily through the development and commercialization of its drug candidates. Revenue streams include potential milestone payments and royalties from licensing agreements with pharmaceutical partners. The company may also generate income from collaborations and partnerships aimed at advancing its drug candidates through clinical trials and towards market approval. Additionally, ZyVersa could explore strategic alliances to leverage shared resources and expertise, contributing to its financial growth.

ZyVersa Therapeutics Financial Statement Overview

Summary

ZyVersa Therapeutics' financial health is strained, with zero revenue, consistent operating losses, and reliance on external financing. The balance sheet shows some improvement with positive equity, but cash flow challenges persist with no free cash flow generation.

Income Statement

ZyVersa Therapeutics has consistently reported zero revenue over the past years, indicating a lack of product commercialization. The net income remains negative, reflecting ongoing losses, and both EBIT and EBITDA margins are negative due to high operational costs without offsetting revenue. The absence of revenue and consistent losses highlight significant challenges in financial performance.

Balance Sheet

The company's balance sheet shows moderate strength in cash reserves relative to total liabilities, with a current net debt position indicating more cash than debt. However, the persistent negative equity in previous years and a lack of revenue-generating assets could pose risks. The current positive stockholders' equity suggests some recovery, but the debt-to-equity ratio is not applicable due to zero total debt.

Cash Flow

ZyVersa's cash flow statement highlights negative operating and free cash flows, indicating challenges in sustaining operations without external financing. The operating cash flow to net income ratio is negative, further emphasizing cash consumption to cover losses. Financing activities have provided cash inflows, crucial for maintaining liquidity, yet the lack of free cash flow growth remains a concern.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-10.40K	-10.40K	-10.40K	-10.40K
	EBIT
-9.14B	-14.42M	-13.01M	-7.70M	-11.83M
	EBITDA
-9.14B	-107.74M	-11.67M	-7.25M	-12.16M
	Net Income Common Stockholders
-9.41B	-98.30M	-759.10M	-8.91M	-13.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.53B	3.14M	5.90M	328.58K	174.67K
	Total Assets
20.60B	22.11M	118.51M	1.13M	685.57K
	Total Debt
0.00	8.66K	108.76K	9.15M	3.82M
	Net Debt
-1.53B	-3.13M	-5.79M	8.82M	3.64M
	Total Liabilities
12.08B	11.04M	18.51M	13.63M	9.24M
	Stockholders Equity
8.52B	11.07M	99.99M	-12.50M	-8.56M
Cash Flow		Free Cash Flow
-7.56B	-8.72M	-1.49M	-5.08M	-5.11M
	Operating Cash Flow
-7.56B	-8.72M	-1.49M	-5.08M	-5.11M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
5.95B	5.96M	―	5.23M	4.56M

ZyVersa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZVSA, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.90, and below the 200-day MA of 1.86, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.32 is Neutral, neither overbought nor oversold. The STOCH value of 8.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZVSA.

ZyVersa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$1.83M	7.04	99.42%	―	―	―
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
ELAB	39 Underperform	$1.97M	―	-130.35%	―	―	―
ZVSA	29 Underperform	$2.41M	―	-96.10%	―	―	99.39%
PTIX	27 Underperform	$1.70M	―	-236.06%	―	―	-40.51%

ZyVersa Therapeutics Corporate Events

ZyVersa Therapeutics’ Shareholder Approvals and Director Elections

ZyVersa Therapeutics’ recent annual meeting saw key shareholder approvals, including the expansion of the 2022 Omnibus Equity Incentive Plan, boosting shares reserved for issuance by 150,000. Stockholders elected Min Chul Park, Ph.D. as a Class II director and ratified Marcum LLP as the independent auditor. Additionally, they approved the issuance of 478,600 shares linked to certain warrants, aligning with Nasdaq rules.